Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ahmed Abdelmoity

Neurology with Special Qualifications in Child Neurology Kansas City, MO Medical Doctor

NPI 1992754337 CMS profile 271378

2401 Gillham Rd, Kansas City, MO 64108

Open in the dashboard

General payments

$1,063,713

1,178 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$15,595 paid to institutions, not to them · program year 2025

Through program year 2025, Ahmed Abdelmoity of Kansas City, MO is reported in the CMS Open Payments database as having received $1,063,713 across 1,178 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $15,595 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $299,879 325
2024 General $232,009 281
2023 General $141,905 168
2022 General $83,950 96
2021 General $67,223 66
2020 General $86,750 85
2019 General $151,997 157

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ahmed Abdelmoity
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Ahmed Abdelmoity were reported at $299,879. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Ahmed Abdelmoity Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $151,997 $262 $68–$1,313 $163
2020 $86,750 $188 $46–$1,222 $114
2021 $67,223 $183 $45–$1,356 $132
2022 $83,950 $229 $72–$1,177 $149
2023 $141,905 $269 $93–$1,195 $160
2024 $232,009 $300 $98–$1,428 $164
2025 $299,879 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LivaNova USA, Inc. $775,921 866 payments
  2. UCB, Inc. $73,352 102 payments
  3. Jazz Pharmaceuticals Inc. $58,773 56 payments
  4. SK Life Science, Inc. $51,300 55 payments
  5. Greenwich Biosciences, Inc. $46,267 46 payments
  6. Neurelis, Inc. $26,356 21 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $10,417 14 payments
  8. Eisai Inc. $7,520 6 payments
  9. Catalyst Pharmaceuticals, Inc. $6,186 4 payments
  10. Biocodex, Inc. $4,553 3 payments
  11. Other $3,068 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $729,563 300 payments
  2. Travel and Lodging $181,378 471 payments
  3. Consulting Fee $66,819 24 payments
  4. Honoraria $56,120 26 payments
  5. Food and Beverage $29,833 357 payments
Products named General payments · program years 2019–2025
  1. VNS THERAPY SENTIVA MODEL 1000 GENERATOR Neurology $352,667 388 payments
  2. VNS Therapy Cardiology/Vascular Diseases $178,491 182 payments
  3. VNS THERAPY SENTIVA MODEL 1000 GENERATOR Cardiology/Vascular Diseases $127,226 142 payments
  4. Epidiolex $105,040 102 payments
  5. VNS Therapy Neurology $87,173 136 payments
  6. Briviact $41,966 53 payments
  7. XCOPRI $40,178 44 payments
  8. VALTOCO $26,356 21 payments
  9. VNS - Sentiva $13,183 7 payments
  10. Cenobamate $11,060 7 payments
  11. Other $47,873 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

1,178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record